REFERENCES


Anderson, DW. (1965):


Blank, H.; Roth, FJ. JR. and Smith, JGJR. (1959):


Borgers and Van Custem, J. (1985):

Botter, A.A. and Nuigen, STM. (1981):


Brian, P.W.; Curtis, PJ. and Hemming, HG. (1946):


Cauwenberg, G.; Degroef, H. and Hey, Kants, J. (1988):


Antifungal chemotherapy, Lancet, 2: 532-537.
Cox, FW.; Stiller, RL. and South, DA. (1981):
Oral ketoconazole for dermatophyte infections.

Crounse, RG. (1961):

Crutcher, N.; Rosenberg, EW. and Belew, PW. (1989):

Cullen, SL. and Cata lano, PM. (1967):
Griseofulvin-warfarine antagonism.
JAMA, 199: 582-583.

Clinical pharmacokinetics of ketoconazole.

Davies, RP.; Everdall, JD. and Hamilton, E. (1967):

Delescluse, J.; Cauwenbergh, G. and Degreel, H. (1986):
Itraconazole, a new orally active antifungal in the treatment of pityriasis versicolor.
Br. J. Dermatol, 14: 701-3.

Dudley, MN. (1990):
Clinical pharmacology of fluconazole, pharmacotherapy 10, No. 6, Part 3: 1415-1455.

Duschinsky, R.; Pleven, E. and Heide Lberger, C. (1957):

El Mazny, HR.; Abdel-Fattah, A. and Abdallah, MA. (1972):
Study of tinea cruris in Egypt, Mykosen, 15: 331.

Epstein, WL.; Shah, VP. and Rigelman, S. (1972):


Ford, GP.; Farr, PM. and Shuster, S. (1984):


Gray Bill, JR. and Craven, PC. (1983):


Greenberg, JR. (1979):

Grave, JF.; Macmillan, J.; Mulholl, TPC. and Rogers, M. (1952):

Gupta, AK.; Brown, MD. and Ellis, CN. (1989):

Hamilton-Miller, JM. (1974):


Hans, F.; Merk, MD. and Hassan Mukhtar, PHD. (1989):

Hay, RJ. (1990):

Heel, RC.; Brogden, RN.; Cormine, A.; Morley, PA. and Speight, TM. (1982):
Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.
Drugs, 23: 1-36.

Heel, RC. (1988):


Holt, RJ. (1980):

Horsburg, CR. and Kirkpatrick, CH. (1983):
Ketoconazole and the liver. Lancet, 1: 860.


Janssen, PAJ. and Symoens, JE. (1983):


Jones, HE. (1982):

Jones, HE. (1984):

Antifungal agents. Systemic Drugs for skin diseases
PP. 25-42.

Lazar, JD. and Wiliner, KD. (1989):
Key drug interaction studies with fluconazole.
Presented at the symposium on major developments in
the management of bacterial and fungal infections,
Vancouver, Canda, August 19-23.

Antifungal agents in dermatology. J. Am. Acad.

Lewis, JH.; Zimmerman, HJ.; Benson, G. and Ishak, KG. (1984):
Hepatic injury associated with ketonazole therapy.
Gastroenterology, 86: 503-510.

Lyell, A. (1967):
A review of toxic epidermal necrolysis in Britian.

Lynch, PJ.; Minkin, W. and Smith, EB. (1969):
Ecology of Candida albicans in candidiasis of the

Marriot, MS.; Andrews, RT.; Richardson, K. and Troke, PP. (1985):
The antifungal activity of UK-49, 858 in animal
models of superficial infections. In : Recent
advances in Chemotherapy. University of Tokyo Press,

Massa, MC. and Rogers, RS. (1981):
Griseofulvin therapy of lichen planus. Acta Derm
Venereol (Stockh), 61: 547-550.
Nauceri, AA.; Cullen, SI.; Vandeveld, AG. et al. (1974):

Medoff, G. and Kobayashi, GS. (1980):

Medoff, G.; Kobayashi, GA. and Speller, DCE. (1980):


Michael, SS. and William, ED. (1988):

Fluconazole pharmacokinetics following oral dosage in leukaemic patients receiving analogous bone marrow transplantation. Bone Marrow Transplant, 3: 324-5.


Nauceri, AA. (1989):
Odds, FC.; Abott, A.B.; Pye, GW. and Troke, PF. (1986):

Paget, GE. and Walpole, AL. (1986):


Pont, A.; Williams, PL. and Azhar, S. (1982):

Richardson, K.; Brammer, JW.; Marriott, MS. and Troke, PF. (1985):

Richardson, K. (1983):

Rippon, JW. (1986):

Roberts, DT. (1982):

Robertson, MH.; Rich, P.; Parkorf, L. and Hanfin, JM. (1982):
Ketoconazole in griseofulvin resistant dermatophytosis. Archives of of Dermatology, 6: 224-229.


Rosenblat, HM.; Bryne, W.; Ament, ME.; Graybill, J. and Stehlm, ER. (1982):

Rosenthal, SA. and Wise, RS. (1960):
Studies concerning the development of resistance to griseofulvin by dermatophytes. Ibid., 684.-

Ryder, NS. and Dupont, MC. (1985):

Ryder, NS. (1989):
Saag, MS. and Dismukes, WE. (1988):
Azole antifungals: Emphasis on new triazole.

Sande, MA. and Mandell, GL. (1985):
New York : Macmillan. 1217-1239.

Savin, RC. (1984):

The interaction of representative members from two classes of antimycotics-the azoles and the allylamines with cytochrome P-450 in steroidogenic tissues and liver. Xenobiotica, 15: 529-46.

Barcelona; Barcelona; JR Prous, 471-7.

Sehgal, VN.; Bikhehandani, R. and Koranne, RV. (1980):
Histopathologic evaluation of griseofulvin therapy in lichen planus: A double blind controlled study.
Dermatologica. 61: 22-27.


Stern, JJ.; Hartman, BJ.; Sharkey, P.; Rawland, V.; Squires, RE.; Murray, HW. and Graybill, JR. (1988):


Stutz, A. (1988):


Suchil Centro, P.; Montero-Gei, FL.; Robles, M.; Perera Ramirez, A.; Welsh, O. and Male, O. (1991):


Toxicology of fluconazole. Recent trends in discovery, development and evaluation of antifungal agents. RA. Fromthing (Ed), JR Prous, Science Publishers, S.A.


Troke, P.F.; Andrews, RT.; Brammer, KW.; Harriot, MS. and Richardson, K. (1985):


Efficacy of fluconazole in animal models of superficial and opportunistic systemic fungal infections. Recent trends in the discovery, development and evaluation of antifungal agents (E.D), JR. Prous Science Publishers, S.A.


Itraconzole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother, 26: 527-534.

Van Custem, J. and Janssen, PAJ. (1985):


The in vitro and in vivo antifungal activity of itraconazole. Recent trends in the discovery, development and evaluation of antifungal agents. RA Fromthing (Ed) JR, Prous Science Publishers, S.A.


Hypothesis on the molecular basis of the antifungal activation of N-substituted imidazoles and triazoles. Biochem. Soc. Trans. 11: 665-667.

Vanden Bossche, H.; Bellens, W.; Cools, J.; Gorrens, P.; Marichal, H.; Verhoeven, G.; Willemsens, R.; De Coster, W.; Lavers and Le Jeune (1986):

Cytochrome P-450: Target for Itraconazole. Drug Dev Res. 8: 298.

Vanden Velde, AG.; Mauceri, AA. and Johnson, JE. (1972):

Van Dyke, CPH. and Weber, JCP. (1984):

Villars, V. and Jones, TC. (1990):

Wilson, JW. (1955):
